



Please type a plus sign (+) inside this box → ☐

PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.			
Substitute for form 1449/PTO			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			
(use as many sheets as necessary)			
Sheet	1	of	1
Application Number		10/050,873	
Filing Date		January 18, 2002	
First Named Inventor		Steven M. Raben	
Group Art Unit		1647	
Examiner Name		F.M. Hamud	
Attorney Docket Number		PZ029P2	

RECEIVED
SEP 29 2003
TECH CENTER 1600/2500

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ²	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ³
FH	AA	FOSSEY, S.C. <i>et al.</i> , "A High-Resolution 6.0-Megabase Transcript Map of the Type 2 Diabetes Susceptibility Region on Human Chromosome 20," <i>Genomics</i> . 76(1-3):45-57 (2001). (abstract)	
FH	AB	LAI, C-H. <i>et al.</i> , "Identification of Novel Human Genes Evolutionarily Conserved in <i>Caenorhabditis elegans</i> by Comparative Proteomics," <i>Genome Res.</i> 10(5):703-13 (2000).	
FH	AC	OHISHI, K. <i>et al.</i> , "PIG-S and PIG-T, Essential for GPI Anchor Attachment to Proteins, Form a Complex with GAA1 and GP18," <i>EMBO J.</i> 20(15):4088-98 (2001).	
FH	AD	OHISHI, K. <i>et al.</i> , "Two Subunits of Glycosylphosphatidylinositol Transamidase, GPI8 and PIG-T, Form a Functionally Important Intermolecular Disulfide Bridge," <i>J. Biol. Chem.</i> 278(16):13959-67 (2003).	
FH	AE	VAINAUSKAS, S. <i>et al.</i> , "Structural Requirements for the Recruitment of Gaal into a Functional Glycosylphosphatidylinositol Transamidase Complex," <i>J. Biol. Chem.</i> 277(34):30535-42 (2002).	
	AF	Genbank Accession No. NP_057021, "Phosphatidylinositol glycan class T precursor [Homo sapiens]," (September 2003).	
	AG	Genbank Accession No. NM_015937, "Homo sapiens phosphatidyl inositol glycan class T (PIGT), mRNA," (September 2003).	
	AH	Genbank Accession No. AX376166, "Sequence 233 from Patent WO0168848," (March 2002).	
	AI	Genbank Accession No. AF132940, "Homo sapiens CGI-06 protein mRNA, complete cds," (May 2000).	
	AJ	Geneseq Accession No. AAY66731, Genentech (1999).	
	AK	Geneseq Accession No. ABU59147, Genentech (2002).	
	AL	Geneseq Accession No. ABU59443, Genentech (2003).	
	AM	Geneseq Accession No. ABU60578, Genentech (2002).	
	AN	Geneseq Accession No. ABU92378, Genentech (2003).	
	AO	Geneseq Accession No. AAY76052, Genesis Res. & Dev. Corp. LTD (1999).	

Examiner Signature	<i>F.M. Hamud</i>	Date Considered	12/11/03
--------------------	-------------------	-----------------	----------

¹ Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Unique citation designation number. ³ See attached Kinds of U.S. Patent Documents. ⁴ Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁷ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.